JP7045388B2 - 安定化されたタンパク質結合カンナビノイド組成物 - Google Patents
安定化されたタンパク質結合カンナビノイド組成物 Download PDFInfo
- Publication number
- JP7045388B2 JP7045388B2 JP2019548645A JP2019548645A JP7045388B2 JP 7045388 B2 JP7045388 B2 JP 7045388B2 JP 2019548645 A JP2019548645 A JP 2019548645A JP 2019548645 A JP2019548645 A JP 2019548645A JP 7045388 B2 JP7045388 B2 JP 7045388B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cannabinoid
- plasma protein
- fatty acid
- plasma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 185
- 239000003557 cannabinoid Substances 0.000 title claims description 122
- 229930003827 cannabinoid Natural products 0.000 title claims description 117
- 102000004169 proteins and genes Human genes 0.000 title claims description 24
- 108090000623 proteins and genes Proteins 0.000 title claims description 24
- 239000000194 fatty acid Substances 0.000 claims description 93
- 102000004506 Blood Proteins Human genes 0.000 claims description 76
- 108010017384 Blood Proteins Proteins 0.000 claims description 76
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 74
- 229930195729 fatty acid Natural products 0.000 claims description 74
- 150000004665 fatty acids Chemical class 0.000 claims description 74
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 61
- 229940065144 cannabinoids Drugs 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 43
- 238000011534 incubation Methods 0.000 claims description 21
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 17
- 235000020778 linoleic acid Nutrition 0.000 claims description 17
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 17
- 102000009027 Albumins Human genes 0.000 claims description 15
- 108010088751 Albumins Proteins 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 8
- 230000002209 hydrophobic effect Effects 0.000 claims description 5
- 230000003993 interaction Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000002131 composite material Substances 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 229960004242 dronabinol Drugs 0.000 description 44
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 43
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 43
- 239000000284 extract Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 20
- 241000218236 Cannabis Species 0.000 description 19
- 241000196324 Embryophyta Species 0.000 description 17
- 239000002609 medium Substances 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- WVOLTBSCXRRQFR-DLBZAZTESA-N cannabidiolic acid Chemical compound OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-N 0.000 description 10
- 238000003860 storage Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 108091006905 Human Serum Albumin Proteins 0.000 description 9
- 102000008100 Human Serum Albumin Human genes 0.000 description 9
- 108060001084 Luciferase Proteins 0.000 description 9
- 239000005089 Luciferase Substances 0.000 description 9
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 9
- 230000015556 catabolic process Effects 0.000 description 9
- 238000006731 degradation reaction Methods 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- UCONUSSAWGCZMV-HZPDHXFCSA-N Delta(9)-tetrahydrocannabinolic acid Chemical compound C([C@H]1C(C)(C)O2)CC(C)=C[C@H]1C1=C2C=C(CCCCC)C(C(O)=O)=C1O UCONUSSAWGCZMV-HZPDHXFCSA-N 0.000 description 7
- 102000003945 NF-kappa B Human genes 0.000 description 7
- 108010057466 NF-kappa B Proteins 0.000 description 7
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 7
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 7
- 229950011318 cannabidiol Drugs 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 7
- KTPDAZGMXXWSMU-UHFFFAOYSA-N Cannabichromen Natural products CCCCc1cc(O)c2C=CC(C)(CCC=C(C)C)Oc2c1 KTPDAZGMXXWSMU-UHFFFAOYSA-N 0.000 description 5
- UVOLYTDXHDXWJU-NRFANRHFSA-N Cannabichromene Natural products C1=C[C@](C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-NRFANRHFSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000012460 protein solution Substances 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 108010058237 plasma protein fraction Proteins 0.000 description 4
- 229940081857 plasma protein fraction Drugs 0.000 description 4
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 description 3
- YSBFLLZNALVODA-RBUKOAKNSA-N JWH-133 Chemical compound C1C(C)=CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCC)=CC=C3[C@@H]21 YSBFLLZNALVODA-RBUKOAKNSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- SSQJFGMEZBFMNV-PMACEKPBSA-N dexanabinol Chemical compound C1C(CO)=CC[C@@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@H]21 SSQJFGMEZBFMNV-PMACEKPBSA-N 0.000 description 3
- 238000003468 luciferase reporter gene assay Methods 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000779 smoke Substances 0.000 description 3
- 108010068307 Alpha-Globulins Proteins 0.000 description 2
- 108010087504 Beta-Globulins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- HQVHOQAKMCMIIM-HXUWFJFHSA-N WIN 55212-2 Chemical compound C([C@@H]1COC=2C=CC=C3C(C(=O)C=4C5=CC=CC=C5C=CC=4)=C(N1C3=2)C)N1CCOCC1 HQVHOQAKMCMIIM-HXUWFJFHSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 229960003453 cannabinol Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- -1 for example Chemical class 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- 239000006163 transport media Substances 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- WVOLTBSCXRRQFR-SJORKVTESA-N Cannabidiolic acid Natural products OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@@H]1[C@@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-SJORKVTESA-N 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000008697 Cannabis sativa Nutrition 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000006150 Marijuana Smoking Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical class O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- HQVHOQAKMCMIIM-UHFFFAOYSA-N win 55,212-2 Chemical compound C=12N3C(C)=C(C(=O)C=4C5=CC=CC=C5C=CC=4)C2=CC=CC=1OCC3CN1CCOCC1 HQVHOQAKMCMIIM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本出願は、米国特許法第119条下で、2017年3月9日に提出された米国仮出願62/469,022の利益を主張し、その内容及び開示は、参照によりその全体に組み込まれる。
本発明の実施形態は、カンナビノイドを含む改良された組成物を提供する。このような組成物を生成する方法もまた本明細書にて提供される。特に下記の本明細書に記載される組成物は含水組成物の場合に安定化する。組成物の安定化は、例えば、組成物の色及び/又はカンナビノイドの分解速度、及び/又は生物活性の保持を観察することにより測定することができる。
カンナビノイドの供給源として大麻樹脂及びハーブ大麻は、貯蔵中に効力を失い、効力の損失は主に、THCなどのカンナビノイドの損失(分解など)によるものであることが長い間認識されてきた。
1.1 リノール酸でのアルブミンの前処理
純粋なリノール酸を50%のエタノールに溶解して、150mMの濃度にした。1mLのリノール酸溶液を10mLの100mg/mL HSA(ヒト血清アルブミン)水溶液に加えた。エタノール濃度が5%未満のリノール酸-HSA溶液を1分間混合し、次いで攪拌せずに37℃で1時間インキュベートした。
工程1.1で調製したリノール酸-HSA溶液を元の濃度の10分の1に水で希釈し、HSA濃度を10mg/mLに削減し、エタノール濃度を約0.5%に削減した。
インキュベーション後、孔径10kDのPellicon XL50カセット(Ultracel)(Pellicon XL Ultra filtration Module Ultracel 10kDa 0.005m2、カタログ番号 PXCO10c50)を使用して、メルク社のCogent μscale装置でDI(脱イオン水)ろ過による洗浄サイクルで透析ろ過により、HSAに結合していないTHC及び脂肪酸の大部分を除去した。その後、リノール酸-THC-HSA複合体を100mlから50mlに該Cogent装置を用いて濃縮した。濃縮リノール酸-THC-HSA複合体試料を3回、300mLの水で洗浄し、最後に洗浄した試料を約20mLの体積に濃縮した。カンナビノイド及び血漿タンパク質のレベルを監視するため、及び3回の洗浄で十分な量の強固に結合した複合体が得られることを測定するために、いくつかの精製段階から試料を採取した。
添加リノール酸の添加を含まない対照THC-HSA組成物(「-L組成物」)は、上記の工程1.1~1.3のとおり調製されたが、工程1.1のリノール酸の添加の工程は行わなかった。最終精製及び濃縮THC-HSA組成物は、66mg/mLの濃度のアルブミン及び1790ug/mLの濃度のTHCを含んでいた。
最終精製及び濃縮の対照THC-アルブミン複合体(「-L」、上記工程1.4の生産物)を含むバイアル及び最終精製及び濃縮のリノール酸-THC-アルブミン複合体(「+L」、上記工程1.3の生産物)を含む別のバイアルは同一条件下、4℃、暗所で保管した。
Claims (19)
- 脂肪酸-カンナビノイド-血漿タンパク質(FCP)組成物を製造するための方法であって、前記方法は:
少なくとも1つの脂肪酸及び少なくとも1つのカンナビノイドが血漿タンパク質又はその一部に結合しているFCP複合体を含む複合組成物が調製されるように、
血漿タンパク質又はそのペプチド部分を、少なくとも1つの脂肪酸を含む補助脂肪酸組成物と接触させること;及び
血漿タンパク質又はその一部を、少なくとも1つのカンナビノイドを含むカンナビノイド組成物と接触させること、
を含み、
少なくとも1つの脂肪酸がリノール酸からなり、
少なくとも1つのカンナビノイドがTHCであり、
血漿タンパク質又はその一部がアルブミンであり、
血漿タンパク質又はその一部への脂肪酸及び/又はカンナビノイドの結合が非共有結合であり、
非共有結合が、血漿タンパク質又はその一部における疎水性タンパク質ポケットとの非特異的な親油性及び極性の相互作用を特徴とする、前記方法。 - カンナビノイド組成物が、血漿タンパク質に結合しない脂肪酸を本質的に含まない、請求項1に記載の方法。
- 複合組成物中の少なくとも80%の脂肪酸及び少なくとも80%のカンナビノイドが、血漿タンパク質又はその一部に結合するように、複合組成物を精製して、血漿タンパク質又はその一部を保持し、かつ血漿タンパク質又はその一部に結合していない脂肪酸又はカンナビノイドを除去することをさらに含む、請求項1に記載の方法。
- 複合組成物中の実質的にすべての脂肪酸及び実質的にすべてのカンナビノイドが、血漿タンパク質又はその一部に結合する、請求項3に記載の方法。
- 血漿タンパク質又はその一部を補助脂肪酸組成物と接触させることには、血漿タンパク質又はその一部を含む組成物を補助脂肪酸組成物と混合し、かつ該混合物をインキュベートすることを含む、請求項1に記載の方法。
- インキュベーションが、摂氏25度(℃)~40℃の温度である、請求項5に記載の方法。
- インキュベーションが、含水アルコール媒体で行われる、請求項5に記載の方法。
- 含水アルコール媒体に含まれるアルコールがエタノールである、請求項7に記載の方法。
- 含水アルコール媒体の初期のアルコール濃度が2%~10%である、請求項7に記載の方法。
- 血漿タンパク質又はその一部をカンナビノイド組成物と接触させることには、血漿タンパク質又はその一部を含む組成物をカンナビノイド組成物と混合し、かつ該混合物をインキュベートすることを含む、請求項1に記載の方法。
- インキュベーションが、摂氏25度(℃)~40℃の温度である、請求項10に記載の方法。
- インキュベーションが、含水アルコール媒体で行われる、請求項10に記載の方法。
- 含水アルコール媒体に含まれるアルコールがエタノールである、請求項12に記載の方法。
- 含水アルコール媒体の初期のアルコール濃度が16%~30%である、請求項12に記載の方法。
- 複合組成物が、含水媒体中で提供される、請求項1に記載の方法。
- 含水媒体が、水又は生理食塩水からなる、請求項15に記載の方法。
- 複合組成物を乾燥又は凍結乾燥することをさらに含む、請求項15に記載の方法。
- 血漿タンパク質又はその一部が組換え体である、請求項1に記載の方法。
- 血漿タンパク質に結合するカンナビノイドの安定性を改善するための方法であって、請求項1の記載に従ってFCP組成物を製造することを含む、前記方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762469022P | 2017-03-09 | 2017-03-09 | |
US62/469,022 | 2017-03-09 | ||
PCT/IL2018/050278 WO2018163187A1 (en) | 2017-03-09 | 2018-03-09 | Stabilized protein-bound cannabinoid compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020510022A JP2020510022A (ja) | 2020-04-02 |
JP7045388B2 true JP7045388B2 (ja) | 2022-03-31 |
Family
ID=63447513
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019548645A Active JP7045388B2 (ja) | 2017-03-09 | 2018-03-09 | 安定化されたタンパク質結合カンナビノイド組成物 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210128519A1 (ja) |
EP (1) | EP3592371B1 (ja) |
JP (1) | JP7045388B2 (ja) |
KR (1) | KR20190122256A (ja) |
CN (1) | CN110545829A (ja) |
AU (1) | AU2018231789B2 (ja) |
BR (1) | BR112019018638A2 (ja) |
CA (1) | CA3055692A1 (ja) |
IL (1) | IL269100B2 (ja) |
RU (1) | RU2019131436A (ja) |
WO (1) | WO2018163187A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
US11202771B2 (en) | 2018-01-31 | 2021-12-21 | Treehouse Biotech, Inc. | Hemp powder |
EP3864000A4 (en) | 2018-10-10 | 2022-08-10 | Treehouse Biosciences, Inc. | CANNABIGEROL SYNTHESIS |
WO2020214220A2 (en) * | 2019-01-15 | 2020-10-22 | Gustin John C | Cannabinoid systems and methods: water-solubility, targeting, and augmentation |
EP3923915A4 (en) * | 2019-02-11 | 2023-03-22 | John Robert Chancey | METHODS OF MAKING AND USING PHYTOCANNABINOIDS COMPLEXED WITH A PROTEIN, PEPTIDE, AMINO ACCHARIDE, POLYSACCHARIDE, DISACCHARIDE, ORMONOSACCHARIDE |
WO2020257588A1 (en) * | 2019-06-20 | 2020-12-24 | Shaman Naturals, Llc | Compositions for preventing and treating viral infections |
US11980593B2 (en) | 2022-07-05 | 2024-05-14 | Poviva Corp. | Compositions and methods for treating hypertension |
US11666544B1 (en) | 2022-07-05 | 2023-06-06 | Poviva Corp. | Compositions and methods for treating hypertension |
US11666543B1 (en) | 2022-07-05 | 2023-06-06 | Poviva Corp. | Pharmaceutical compositions and methods for treating hypertension |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015140736A1 (en) | 2014-03-18 | 2015-09-24 | Izun Pharmaceuticals Corp. | Protein-bound cannabinoid compositions |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04208280A (ja) * | 1990-11-30 | 1992-07-29 | Matsushita Electric Ind Co Ltd | カンナビノール誘導体とその作製方法及びカンナビノール・タンパク質コンジュゲート |
GB9726916D0 (en) * | 1997-12-19 | 1998-02-18 | Danbiosyst Uk | Nasal formulation |
WO2017137992A1 (en) * | 2016-02-11 | 2017-08-17 | Gelpell Ag | Oral solid cannabinoid formulations, methods for producing and using thereof |
-
2018
- 2018-03-09 EP EP18763376.3A patent/EP3592371B1/en active Active
- 2018-03-09 KR KR1020197029411A patent/KR20190122256A/ko not_active Application Discontinuation
- 2018-03-09 WO PCT/IL2018/050278 patent/WO2018163187A1/en unknown
- 2018-03-09 JP JP2019548645A patent/JP7045388B2/ja active Active
- 2018-03-09 CA CA3055692A patent/CA3055692A1/en active Pending
- 2018-03-09 IL IL269100A patent/IL269100B2/en unknown
- 2018-03-09 US US16/492,142 patent/US20210128519A1/en active Pending
- 2018-03-09 CN CN201880027907.3A patent/CN110545829A/zh active Pending
- 2018-03-09 AU AU2018231789A patent/AU2018231789B2/en active Active
- 2018-03-09 RU RU2019131436A patent/RU2019131436A/ru unknown
- 2018-03-09 BR BR112019018638A patent/BR112019018638A2/pt unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015140736A1 (en) | 2014-03-18 | 2015-09-24 | Izun Pharmaceuticals Corp. | Protein-bound cannabinoid compositions |
Non-Patent Citations (2)
Title |
---|
Advances in Molecular and Cell Biology,2003年,33,29-46 |
Current Pharmaceutical Design,2015年,21(14),1862-1865 |
Also Published As
Publication number | Publication date |
---|---|
AU2018231789B2 (en) | 2024-02-22 |
EP3592371C0 (en) | 2023-06-07 |
US20210128519A1 (en) | 2021-05-06 |
IL269100B2 (en) | 2024-05-01 |
AU2018231789A1 (en) | 2019-10-24 |
EP3592371A1 (en) | 2020-01-15 |
JP2020510022A (ja) | 2020-04-02 |
KR20190122256A (ko) | 2019-10-29 |
IL269100A (en) | 2019-11-28 |
BR112019018638A2 (pt) | 2020-04-07 |
EP3592371A4 (en) | 2021-01-13 |
IL269100B1 (en) | 2024-01-01 |
RU2019131436A3 (ja) | 2021-05-25 |
EP3592371B1 (en) | 2023-06-07 |
WO2018163187A1 (en) | 2018-09-13 |
CN110545829A (zh) | 2019-12-06 |
RU2019131436A (ru) | 2021-04-10 |
CA3055692A1 (en) | 2018-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7045388B2 (ja) | 安定化されたタンパク質結合カンナビノイド組成物 | |
Sahu et al. | Wheat phenolics suppress doxorubicin-induced cardiotoxicity via inhibition of oxidative stress, MAP kinase activation, NF-κB pathway, PI3K/Akt/mTOR impairment, and cardiac apoptosis | |
Choi et al. | Angiogenic activity of β-sitosterol in the ischaemia/reperfusion-damaged brain of Mongolian gerbil | |
Chen et al. | Quercetin protects the vascular endothelium against iron overload damages via ROS/ADMA/DDAHⅡ/eNOS/NO pathway | |
Carullo et al. | Vasoactivity of Mantonico and Pecorello grape pomaces on rat aorta rings: An insight into nutraceutical development | |
Viera et al. | First‐pass metabolism of chlorophylls in mice | |
Kaur et al. | Beneficial effect of rice bran extract against 3-nitropropionic acid induced experimental Huntington's disease in rats | |
Du et al. | Dexamethasone attenuates LPS-induced changes in expression of urea transporter and aquaporin proteins, ameliorating brain endotoxemia in mice | |
Liu et al. | Lonicera caerulea berry polyphenols extract alleviates exercise fatigue in mice by reducing oxidative stress, inflammation, skeletal muscle cell apoptosis, and by increasing cell proliferation | |
Kubczak et al. | Hippophae rhamnoides L. leaf and twig extracts as rich sources of nutrients and bioactive compounds with antioxidant activity | |
Koppula et al. | Anti-fibrotic effects of Orostachys japonicus A. Berger (Crassulaceae) on hepatic stellate cells and thioacetamide-induced fibrosis in rats | |
Corsetti et al. | Essential amino acid supplementation decreases liver damage induced by chronic ethanol consumption in rats | |
Salama et al. | Cross-talk between PPARγ, NF-κB, and p38 MAPK signaling mediates the ameliorating effects of bergenin against the iron overload-induced hepatotoxicity | |
Palani et al. | In vivo analysis of nephro & hepato protective effects and antioxidant activity of Madhuca longifolia against acetaminophen-induced toxicity & oxidative stress | |
Palanisamy et al. | Nigella sativa L. seed extracts promote wound healing progress by activating VEGF and PDGF signaling pathways: An in vitro and in silico study | |
Rosado-Ramos et al. | Genipin prevents alpha-synuclein aggregation and toxicity by affecting endocytosis, metabolism and lipid storage | |
Yang et al. | Neuroprotective effects of a butanol fraction of Rosa hybrida petals in a middle cerebral artery occlusion model | |
CN104161732A (zh) | 注射用奥美拉唑钠及其制备方法和用途 | |
Anandan et al. | Bioactive compounds from Morus indica as inhibitors of advanced glycation end products | |
JP2013107852A (ja) | メイラード反応阻害剤 | |
Assis et al. | Potassium channel activation is involved in the cardiovascular effects induced by freeze dried Syzygium jambolanum (Lam.) DC fruit juice | |
Palani1&3 et al. | Evaluation of nephroprotective and antioxidant potential of Tragia involucrata | |
Almalki | Citrus aurantium flowers essential oil protects liver against ischemia/reperfusion injury | |
Abou Khalil et al. | Cinnamaldehyde and cinnamic acid from cinnamon bark (Cinnamomum verum) increase the binding of glucose to human albumin | |
Sekar et al. | Determination of allicin in Allium sativum using high performance liquid chromatography and study of genotoxic effect on human leukocytes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210216 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20211119 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220222 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220308 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220318 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7045388 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |